Media stories about EXACT Sciences (NASDAQ:EXAS) have been trending positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. EXACT Sciences earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 45.9940371253393 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
Get EXACT Sciences alerts:
Exact Sciences launches $150M convertible debt offering (seekingalpha.com) Exact Sciences Announces Offering of 1.0% Convertible Senior Notes Due 2025 (finance.yahoo.com) This Biotech Said It Can Detect Liver Cancer In Your Blood And Broke Out (finance.yahoo.com) Canaccord Genuity Reaffirms Buy Rating for EXACT Sciences (EXAS) (americanbankingnews.com) BIIB’s Alzheimer’s Drug Scores Well, EXAS Heads Higher, VXRT Down But Not Out (nasdaq.com)
A number of equities analysts recently issued reports on the stock. BidaskClub upgraded shares of EXACT Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Canaccord Genuity upped their price target on shares of EXACT Sciences from $68.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday. Zacks Investment Research upgraded shares of EXACT Sciences from a “sell” rating to a “hold” rating in a research note on Monday. BTIG Research reiterated a “buy” rating on shares of EXACT Sciences in a research note on Tuesday. Finally, Robert W. Baird upped their price target on shares of EXACT Sciences from $58.00 to $66.00 and gave the stock an “outperform” rating in a research note on Tuesday. Five analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. EXACT Sciences currently has an average rating of “Buy” and an average price target of $58.82.
Shares of EXACT Sciences opened at $63.20 on Friday, Marketbeat.com reports. EXACT Sciences has a fifty-two week low of $31.04 and a fifty-two week high of $67.50. The company has a quick ratio of 14.86, a current ratio of 15.30 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $7.61 billion, a price-to-earnings ratio of -63.84 and a beta of 0.86.
EXACT Sciences (NASDAQ:EXAS) last issued its earnings results on Thursday, April 26th. The medical research company reported ($0.33) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.38) by $0.05. EXACT Sciences had a negative return on equity of 20.92% and a negative net margin of 38.61%. The business had revenue of $90.30 million during the quarter, compared to analyst estimates of $86.31 million. During the same quarter in the previous year, the firm earned ($0.32) EPS. EXACT Sciences’s revenue was up 86.7% on a year-over-year basis. sell-side analysts forecast that EXACT Sciences will post -1.18 earnings per share for the current year.
In other EXACT Sciences news, Director Thomas D. Carey sold 8,448 shares of the business’s stock in a transaction dated Tuesday, April 10th. The stock was sold at an average price of $39.73, for a total value of $335,639.04. Following the completion of the transaction, the director now owns 52,610 shares of the company’s stock, valued at approximately $2,090,195.30. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP D Scott Coward sold 2,708 shares of the company’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $52.19, for a total transaction of $141,330.52. The disclosure for this sale can be found here. In the last three months, insiders sold 44,666 shares of company stock valued at $2,143,361. 3.20% of the stock is owned by insiders.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.